The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous α-lipoic acid/low-dose naltrexone protocol

Integrative Cancer Therapies

Volumn 5, Issue 1, 2006, Pages 83-89

  Berkson, Burton M ^a   Rubin, Daniel M ^b   Berkson, Arthur J ^b,c  

^a NEW MEXICO STATE UNIVERSITY   (United States)

^b Illinois Masonic Medical Center ^*  (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Lipoic acid; Naltrexone; Pancreatic cancer; Survival

Indexed keywords

ALPRAZOLAM; ANTIOXIDANT; BISMUTH SALICYLATE; CARBOPLATIN; DIHYDROXYALUMINUM SODIUM CARBONATE; GEMCITABINE; LANSOPRAZOLE; MYLANTA; NALTREXONE; SELENIUM; SILYMARIN; SULFAMETHOXAZOLE; THIOCTIC ACID; TRIMETHOPRIM;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CASE REPORT; CLINICAL FEATURE; CLINICAL PROTOCOL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; GENE THERAPY; HUMAN; LIFESTYLE; LIVER METASTASIS; MALE; PANCREAS CANCER; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NALTREXONE; NEOPLASM STAGING; PALLIATIVE CARE; PANCREATIC NEOPLASMS; THIOCTIC ACID; TIME FACTORS; TREATMENT OUTCOME;

EID: 32944472049     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735405285901     Document Type: Article

References (24)

1. van Stiegmann G, Bornman P, Terblanche J. Carcinoma of the pancreas at Groote Schuur Hospital, 1975-1979. S Afr Med J. 1981 ; 60: 97-99.
2. Bornman P, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system: pancreatic tumours. BMJ. 2001 ; 322: 721-723.
3. Choi SB, Lee Hy, Yuh YJ, Kim SR. A phase 2 study of combination chemotherapy with gemcitabine, 5-florourouracil, and cisplantin for advanced pancreatic cancer [in Korean]. Korean J Gastroenterol. 2005 ; 45: 348-353.
4. Brown TT, Zelnik DL, Dobs AS. Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients. Int J Gastrointest Cancer. 2003 ; 34: 143-150.
5. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol. 2004 ; 3: 173-189.
6. Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med Klin (Munich). 1999 ; 94 (suppl 3). 84-89.
7. Berkson BM. Thioctic acid in treatment of hepatotoxic mushroom (Phalloides) poisoning. N Engl J Med. 1979 ; 300: 371.
8. Wenzel U, Nickel A, Daniel H. Alpha-lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-.-generation. Apoptosis. 2005 ; 10: 359-368.
9. Van de Mark K, Chen JS, Steliou K, et al. Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J Cell Physiol. 2003 ; 194: 325-340.
10. Lee KY, D'Acquisto F, Hayden MS, et al. PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation. Science. 2005 ; 308: 114-118.
11. Sokoloski JA, Hodnick WF, Mayne ST, et al. Induction of the differentiation of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: possible relationship to NF-kappaB. Leukemia. 1997 ; 11: 1546-1553.
12. Suzuki YJ, Aggarwal BB, Packer L. Alpha-lipoic acid is a potent inhibitor of NF-kappa B activation in human T cells. Biochem Biophys Res Commun. 1992 ; 189: 1709-1715.
13. Casciari JJ, Riordan NH, Schmidt TL, Meng XL, Jackson JA, Riordan HD. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br J Cancer. 2001 ; 84: 1544-1550.
14. Mantovani G, Maccio A, Madeddu C, et al. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med. 2003 ; 81: 664-673.
15. Hultberg B. Modulation of extracellular homocysteine concentration in human cell lines. Clin Chim Acta. 2003 ; 330 (1-2). 151-159.
16. Pack RA, Hardy K, Madigan MC, Hunt NH. Differential effects of the antioxidant alpha-lipoic acid on the proliferation of mitogen-stimulated peripheral blood lymphocytes and leukaemic T cells. Mol Immunol. 2002 ; 38: 733-745.
17. Mantovani G, Maccio A. Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. Int J Cancer. 2000 ; 86: 842-847.
18. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science. 1983 ; 221: 671-673.
19. Zagon IS, McLaughlin PJ. Opioids and the apoptotic pathway in human cancer cells. Neuropeptides. 2003 ; 37: 79-88.
20. Lissoni P, Meregalli S, Fossati V, et al. Radioendocrine therapy of brain tumors with the long acting opioid antagonist naltrexone in association with radiotherapy. Tumori. 1993 ; 79: 198-201.
21. Lissoni P, Malugani F, Malysheva O, et al. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system. Neuro Endocrinol Lett. 2002 ; 23: 341-344.
22. Bihari B. Efficacy of low dose naltrexone as an immune stabilizing agent for the treatment of HIV/AIDS [letter]. AIDS Patient Care. 1995 ; 9 (1). 3.
23. Bilhari B. LDN and cancer [Low Dose Naltrexone Web Site]. Available at: http://www.lowdosenaltrexone.org. Accessed December 8, 2005.
24. Bilhari B. Keynote address. Presented at: First Annual Low Dose Naltrexone Conference at the New York Academy of Sciences ; June 11, 2005 ; New York, NY.